Wells Fargo
NKGN

Wells Fargo’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Wells Fargo’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-48
Closed -$91 – 7600
2024
Q1 		$91 Buy
48
+1
+2% +$2 ﹤0.01% 6687
2023
Q4 		$129 Buy
+47
New +$152 ﹤0.01% 6709

Other funds holding NKGN

MC
Meteora Capital Boca Raton, Florida $1.36B AUM 20.06% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
UOC
University of Chicago Chicago, Illinois $323M AUM 14.1% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $385M AUM 31.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return

Wells Fargo's NKGN Position: Q2 2024 in Review

Wells Fargo sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q2 2024, closing a stake of 48 shares — an estimated $91 sold.

Wells Fargo first reported a position in NKGN in Q4 2023 and held it in 2 quarters. The position peaked at $129 in Q4 2023. 17 funds tracked by Wall St. Rank hold NKGN as of Q2 2024.

  • Wells Fargo reported no remaining NKGen Biotech, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Wells Fargo sold 48 NKGen Biotech, Inc. Common Stock shares in Q2 2024, an estimated $91.
  • Wells Fargo first reported a position in NKGen Biotech, Inc. Common Stock in Q4 2023 and held it in 2 quarters.
  • Wells Fargo's NKGen Biotech, Inc. Common Stock position peaked at $129 in Q4 2023.
  • 17 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.